Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H18ClNO2 |
Molecular Weight | 255.741 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(NC(C)(C)CO)C(=O)C1=CC(Cl)=CC=C1
InChI
InChIKey=AKOAEVOSDHIVFX-UHFFFAOYSA-N
InChI=1S/C13H18ClNO2/c1-9(15-13(2,3)8-16)12(17)10-5-4-6-11(14)7-10/h4-7,9,15-16H,8H2,1-3H3
Molecular Formula | C13H18ClNO2 |
Molecular Weight | 255.741 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Bupropion is an atypical antidepressant that also has usefulness as a smoking-cessation aid. Because hydroxybupropion, a major metabolite of bupropion, is believed to contribute to its antidepressant activity, this metabolite may also contribute to the smoking-cessation properties of bupropion. Compared to bupropion hydroxybupropion inhibit norepinephrine (NE) uptake with similar potency. The effects of bupropion and enantiomers of hydroxybupropion on human nAChR subtypes indicate that the (2S,3S) isomer is more potent than the (2S,3R) isomer or racemic bupropion as an antagonist of alpha(4)beta(2) subtypes of nicotinic acetylcholine receptor (nAChR). In addition, both isomers of hydroxybupropion possess weaker antagonist activity to the alpha3/beta4 and alpha4/beta4 subtypes of nAChR.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26916207
Curator's Comment: Known to be CNS penetrant in rat. Human data not available
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q01959 Gene ID: 6531.0 Gene Symbol: SLC6A3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15322260 |
790.0 nM [IC50] | ||
Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15322260 |
|||
Target ID: CHEMBL1907589 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15322260 |
3.3 µM [IC50] | ||
Target ID: CHEMBL1907591 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15322260 |
|||
Target ID: CHEMBL1907594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15322260 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. | 2004 Sep |
|
Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach. | 2009 Feb |
|
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. | 2012 Dec |
|
Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma. | 2016 Apr 1 |
|
Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations. | 2016 May |
|
Design of experiment assisted concurrent enantioseparation of bupropion and hydroxybupropion by high-performance thin-layer chromatography. | 2017 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18623203
Male and female Hairless IAF and Hartley guinea pigs: For i.v. bolus experiments, a dose of 1 mg/kg for both bupropion (BUP) and hydroxybupropion (BUPOH) were infused over a period of 30 s. For transdermal delivery, the developed TTS patches (two patches, 14.5 cm2 diffusional area) were applied to the dorsal region of the hairless guinea pigs. Blood samples were obtained for 48 h while patches were on the animal, and for another 48 h after patches were removed. Blood samples were obtained for 72 h following intravenous administration
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15322260
Bupropion analogs were evaluated in neurotransmitter uptake assays using synaptosomes prepared from rat brain (adult male Sprague-Dawley rats weighing 250g). Because no significant differences between rat and human synaptosomes were observed in studies of monoamine uptake data obtained using rat tissue should predict the behavior of these compounds at the corresponding human transporter. Bupropion is a relatively weak inhibitor of DA uptake with an IC50 of 550 nM, and it is even less potent as an inhibitor of NE reuptake. Compared with bupropion, its racemic hydroxyl metabolite produces equal inhibition of NE reuptake and much weaker inhibition of DA uptake. The (2S,3S isomer is the active form ), whereas the(2S,3R) isomer shows no significant inhibition of either DA or NE uptake. Compared with bupropion, (2S,3S)-hydroxybupropion produce similar or stronger inhibition of DA and NE uptake, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:58:24 GMT 2023
by
admin
on
Sat Dec 16 09:58:24 GMT 2023
|
Record UNII |
V94F513635
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
446
Created by
admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
|
PRIMARY | |||
|
DTXSID101002894
Created by
admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
|
PRIMARY | |||
|
HYDROXYBUPROPION
Created by
admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
|
PRIMARY | |||
|
82793-84-8
Created by
admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
|
SUPERSEDED | |||
|
V94F513635
Created by
admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
|
PRIMARY | |||
|
92264-81-8
Created by
admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
|
PRIMARY | |||
|
357399-43-0
Created by
admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
|
ALTERNATIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |